A retrospective study of predictive factors for unexpectedly prolonged or shortened progression-free survival and overall survival among patients with metastatic renal cell carcinoma who received first-line targeted therapy

Table 3 Predictive factors for progression-free survival after comparing the expected group and the group with the best response to therapy

	Univariate			Multivariate
				MSKCC risk patients			Heng risk patients
Variables	OR	P-value	95 % CI	HR	P-value	95 % CI	HR	P-value	95 % CI
Heng Intermediate risk group	0.25	0.019	0.08–0.8				0.32	0.083	0.09–1.16
Poor	0.09	0.111	0.01–1.76				0.25	0.414	0.01–7.0
Nx	7.31	0.012	1.56–34.33	7.15	0.016	1.43–35.67	3.90	0.076	0.87–17.56

ISSN: 1471-2407